Literature DB >> 32199085

Old and new breakthroughs in neuromyelitis optica.

Hans-Peter Hartung1, Orhan Aktas2.   

Abstract

Entities:  

Year:  2020        PMID： 32199085     DOI： 10.1016/S1474-4422(20)30062-4

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  5 in total

Review 1.  Neuroinflammation in Parkinson's Disease - Putative Pathomechanisms and Targets for Disease-Modification.

Authors:  Alexander Grotemeyer; Rhonda Leah McFleder; Jingjing Wu; Jörg Wischhusen; Chi Wang Ip
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

2.  Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222).

Authors:  Gustavo C Román; Fernando Gracia; Antonio Torres; Alexis Palacios; Karla Gracia; Diógenes Harris
Journal:  Front Immunol       Date:  2021-04-26       Impact factor: 7.561

3.  Are aquaporin antibody titers useful outcome measures for neuromyelitis optica spectrum disorders?

Authors:  Markus Reindl
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-05-28

Review 4.  Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2.

Authors:  Jonas Graf; Jan Mares; Michael Barnett; Orhan Aktas; Philipp Albrecht; Scott S Zamvil; Hans-Peter Hartung
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-12-16

Review 5.  COVID-19 and management of neuroimmunological disorders.

Authors:  Hans-Peter Hartung; Orhan Aktas
Journal:  Nat Rev Neurol       Date:  2020-07       Impact factor: 44.711
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.